Biotechnology
A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge
An in-depth analysis of the massive wave of pharmaceutical mergers and acquisitions in the first half of 2026, driven by patent cliffs, pipeline replenishment, and high-growth therapeutic areas.
Pharmaceutical
The Innovation Exodus: Why Europe Must Rethink Medicine Pricing or Risk Losing Life Science Investments
An in-depth analysis of the warnings from pharmaceutical lobby chief Stefan Oelrich regarding European cost-cutting reforms, global pricing shifts, and the threat to clinical research and manufacturing.
Pharmaceutical
Scaling Ireland’s Biopharma Leadership: Inside Eli Lilly’s $2.8 Billion Manufacturing Expansion in Limerick and Kinsale
An in-depth analysis of Eli Lilly’s massive manufacturing footprint in Limerick and Kinsale, highlighting local jobs, high-tech biologic drug production, and Ireland’s strategic position in the global biopharma supply chain.
Pharmaceutical
Roche Seeks Buyer for Former Manufacturing Site in Clarecastle, Co Clare - €4m Price Tag
Swiss pharma giant Roche has appointed Cushman & Wakefield to sell its 88-acre decommissioned manufacturing facility in Clarecastle, Co Clare, with an expected asking price of €4 million, following a €150m remediation programme.
Industry
Ireland Tightens Family Reunification Rules: Higher Income Thresholds, Housing Checks and Stricter Relationship Scrutiny
The Irish Department of Justice has overhauled its family reunification framework, raising the income requirement for Irish citizen sponsors to €75,000 over three years, introducing housing sufficiency checks, and imposing a new two-year waiting period for refugees. Here is everything migrants and families in Ireland need to know.
Pharmaceutical
Status Yellow High Temperature Warning Issued for Ireland - Your Complete Health & Safety Guide
Met Éireann has issued a Status Yellow High Temperature Warning for Ireland. Here is everything you need to know: how to protect yourself and your family, what to eat and drink, what to keep at home, and the key precautions recommended by HSE and public health experts.
LinkedIn
LinkedIn for Medical Science Liaisons (MSLs): The Complete Guide to Showcasing Scientific Expertise Without Violating Compliance
A step-by-step compliance-safe LinkedIn guide exclusively for Medical Science Liaisons. Covers profile optimisation, what to post, what never to post, KOL engagement, off-label rules, digital medical affairs strategy, and how to build scientific credibility on LinkedIn without breaching pharmaceutical regulatory guidelines.
Regulatory Affairs
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.
LinkedIn
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.
Industry
U.S. Initiates Tariff Probe into Germany’s Pharmaceutical Pricing Policies
The United States has formally launched a trade investigation under Section 301 into Germany’s drug reimbursement practices, citing concerns that domestic price controls unfairly burden American innovation.
Biotechnology
Global Biopharma Layoff Tracker Report (2025-2026): A Structural Reshaping
A detailed global report analyzing major pharmaceutical and biotech layoffs across the US, EU, and India from 2025 to 2026, including strategic shifts by enGene, Takeda, Bayer, and BioNTech.
Biotechnology
Global Pharma Giants Pledge $500 Billion in U.S. Investments
Drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively announced approximately $500 billion in U.S. investments aimed at strengthening infrastructure and reducing supply-chain vulnerabilities.